212842-64-3

Usage

Uses

Used in Pharmaceutical Industry:
Cowaxanthone B is used as a potential pharmaceutical agent for its anti-inflammatory properties, offering a natural alternative for the treatment of inflammation-related conditions. Its antioxidant capabilities also contribute to its potential use in combating oxidative stress associated with various diseases.
Used in Oncology:
In the field of oncology, Cowaxanthone B is utilized as a cytotoxic agent, specifically for its ability to inhibit the growth of cancer cells. This makes it a candidate for further research and development in cancer treatment, potentially leading to new therapeutic options for patients.
Used in Antimicrobial Applications:
Cowaxanthone B is employed as an antimicrobial agent due to its demonstrated properties against certain microorganisms. This expands its potential applications in medicine and healthcare, particularly in the development of new antibiotics or antifungal agents to combat drug-resistant infections.

Upstream product

• 6147-11-1 α-mangostin 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

Modified tetra-oxygenated xanthones analogues as anti-MRSA and P. aeruginosa agent and their synergism with vancomycin

Five isolated xanthones from the C. cochinchinense and G. mangostana were evaluated and tested for antibacterial activities. Isolated 4 and 5 exhibited potent anti-MRSA and P. aeruginosa activity, but showed poor pharmacokinetic properties via ADMET prediction. It led us to improve pharmacokinetic properties of 4 and 5 by partially modifying them in acidic condition yielding fourteen analogues. It was found that analogues 4b, 4d and 5b possessed proper pharmacokinetic properties, while only 4b exhibited the best anti-MRSA and P. aeruginosa activity. The SEM results indicated that 4b may interact with or damage the cell wall of MRSA and P. aeruginosa. Moreover, a combination of 4b and vancomycin exhibits synergistic effect against both MRSA and P. aeruginosa at MIC value of 4.98 (MIC = 18.75 μg/mL for 4b) and 9.52 μg/mL (MIC = 75 μg/mL for 4b), respectively.

Chemistry of α-mangostin. Studies on the semisynthesis of minor xanthones from Garcinia mangostana

α-Mangostin is the major prenylated xanthone from Garcinia mangostana and it has been used also in recent times as starting material for the semisynthetic preparation of various biologically active derivatives. Its structure is characterised by the presence of few functional groups amenable to chemical manipulations, but present in the molecule in multiple instances (three phenolic hydroxyl groups, two prenyl chains and two unsubstituted aromatic carbons). This study represents a first approach to the systematic investigation of the reactivity of α-mangostin and describes the semisynthesis of some minor xanthones isolated from G. mangostana.

Potent activity against multidrug-resistant Mycobacterium tuberculosis of α-mangostin analogs

A new series of mangostin analogs of natural α-mangostin from mangosteen was prepared and their antimycobacterial activity was evaluated in vitro against Mycobacterium tuberculosis H37Ra. The results showed that the monoalkyl tetrahydro α-mangostin analogs displayed increased antimycobacterial activity as compared with the lead natural xanthone, α-mangostin. Among the tested compounds, 6-methoxytetrahydro α-mangostin (16) exhibited the most potent antimycobacterial activity with minimum inhibitory concentration (MIC) of 0.78 μg/mL. The activity of the monoalkylated and monoacylated tetrahydro α-mangostins decreases as the length of carbon chain increases. The methyl ether analog was also active against the multidrug- resistant (MDR) strains with pronounced MICs of 0.78-1.56 μg/mL.